A5051714890- Inflammatory Bowel Disease
- Genetic Associations and Epidemiology
- Bioinformatics and Genomic Networks
- Gene expression and cancer classification
- Microscopic Colitis
- Immunodeficiency and Autoimmune Disorders
- Genetic Mapping and Diversity in Plants and Animals
- Helicobacter pylori-related gastroenterology studies
- Genetic and phenotypic traits in livestock
- Asthma and respiratory diseases
- Celiac Disease Research and Management
- Gut microbiota and health
- Systemic Lupus Erythematosus Research
- Eosinophilic Esophagitis
- Epigenetics and DNA Methylation
- Immune Cell Function and Interaction
- Health, Environment, Cognitive Aging
- Autoimmune and Inflammatory Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Cancer survivorship and care
- Metabolomics and Mass Spectrometry Studies
- IL-33, ST2, and ILC Pathways
- Machine Learning in Bioinformatics
- T-cell and B-cell Immunology
University of Liège
2016-2025
KU Leuven
2016-2025
Ege University
2024
VIB-KU Leuven Center for Cancer Biology
2024
Institut thématique Génétique, génomique et bioinformatique
2023
Walloon Excellence in Lifesciences and Biotechnology
2017-2022
Université Stendhal – Grenoble 3
2020-2021
Leiden University
2021
VIB-UAntwerp Center for Molecular Neurology
2018
University of Antwerp
2018
Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on long-term outcome IFX CD is still debated.We studied during 214 patients. A total 183 (85.5%) responded to induction therapy and 31 (14.5%) were primary nonresponders. They underwent lower gastrointestinal (GI) endoscopy within a median 0.7 months (interquartile range [IQR] 0.1-6.8) prior first after 6.7 (IQR 1.4-24.6) start further analyzed. The relationship between was...
<h3>Background and aims:</h3> This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre during median follow-up 55 months (interquartile range (IQR) 27–83). <h3>Methods:</h3> The primary analysis looked at proportion initial response to IFX who had sustained end follow-up. effects on course CD as reflected by rate surgery hospitalisations need for corticosteroids were also analysed....
<h3>Background and aims:</h3> Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to up 30% reaching remission. The mechanism resistance anti-tumour necrosis factor α (anti-TNFα) unknown. This study used colonic mucosal gene expression provide a predictive response signature infliximab in colitis. <h3>Methods:</h3> Two cohorts who received their first refractory were studied. Response was defined as endoscopic histological healing. Total RNA from...
Antimicrobial peptides (AMPs) protect the host intestinal mucosa against microorganisms. Abnormal expression of defensins was shown in inflammatory bowel disease (IBD), but it is not clear whether this a primary defect. We investigated impact anti-inflammatory therapy with infliximab on mucosal gene AMPs IBD.Mucosal 81 assessed 61 IBD patients before and 4-6 weeks after their first infusion 12 control patients, using Affymetrix arrays. Quantitative real-time reverse-transcription PCR...
OBJECTIVES: Endoscopic mucosal healing is a key endpoint for the treatment of ulcerative colitis (UC). The role microscopic activity in predicting disease relapse has not been fully assessed. We aimed to investigate predictive serologic and histologic markers on UC patients with endoscopically inactive disease. METHODS: Adult (Mayo 0) 12-month follow-up between 2008 2011 were retrospectively included. An expert pathologist evaluated all colonic biopsies (Geboes score) presence basal...
<b>Background and aims:</b> Several antibodies have been associated with Crohn's disease are distinct clinical phenotypes. The aim of this study was to determine whether a panel new against bacterial peptides glycans could help in differentiating inflammatory bowel (IBD), they were particular manifestations. <b>Methods:</b> Antibodies mannan epitope <i>Saccharomyces cerevisiae</i> (gASCA), laminaribioside (ALCA), chitobioside (ACCA), mannobioside (AMCA), outer membrane porins (Omp) the...
BackgroundEvidence that a deficient innate immune response toward the bacterial flora of gut plays role in pathogenesis inflammatory bowel disease (IBD) is growing. This underscored by finding association between CARD15 variants and Crohn's (CD) D299G Toll-like receptor (TLR) 4 IBD. Our aims were to study nonsynonymous polymorphisms other TLR genes
Infliximab (IFX) has been shown efficacious for moderate-to-severe ulcerative colitis (UC), but data on long-term efficacy are lacking. We investigated outcome including colectomy rates in outpatients treated with IFX refractory UC a single referral centre, and evaluated if predictors could be identified.The first 121 (median age 38.0 years) were included. The primary was colectomy-free survival. Secondary measures sustained clinical response serious adverse events.From the 81 patients (67%)...
Infliximab (IFX) and adalimumab (ADA) are attractive treatment options in patients with inflammatory bowel disease (IBD) also during pregnancy but there is still limited data on the benefit/risk profile of IFX ADA pregnancy. This observational study assessed outcomes 212 women IBD under antitumor necrosis factor alpha (TNF) at our unit. Pregnancy 42 pregnancies direct exposure to anti-TNF (35 IFX, 7 ADA) were compared that 23 prior diagnosis, 78 before start 53 indirect 56 matched healthy...
We performed risk assessment for Crohn's disease (CD) and ulcerative colitis (UC), the two common forms of inflammatory bowel (IBD), by using data from International IBD Genetics Consortium's Immunochip project. This set contains ∼17,000 CD cases, ∼13,000 UC ∼22,000 controls 15 European countries typed on Immunochip. custom chip provides a more comprehensive catalog most promising candidate variants picking up remaining certain rare that were missed in first generation GWAS. Given this...
Infliximab (IFX) has become the mainstay of therapy refractory Crohn's disease (CD). However, a subset patients shows incomplete or no response to this agent. In study we investigated whether could identify mucosal gene panel predict (non)response IFX in CD.Mucosal biopsies were obtained during endoscopy from 37 with active CD (19 colitis [CDc] and 18 ileitis [CDi]) before after first treatment. Response was defined based on endoscopic histologic findings. Total RNA analyzed Affymetrix Human...